



# HHS Public Access

Author manuscript

*Nat Med.* Author manuscript; available in PMC 2019 December 01.

Published in final edited form as:

*Nat Med.* 2018 December ; 24(12): 1804–1808. doi:10.1038/s41591-018-0238-9.

## Fecal Microbiota Transplantation for refractory immune checkpoint inhibitor-associated colitis

Yinghong Wang, MD, PhD<sup>1,\*,#,‡</sup>, Diana H. Wiesenki<sup>2,‡</sup>, Beth A. Helmink, MD, PhD<sup>3,‡</sup>, Vancheswaran Gopalakrishnan, PhD<sup>3</sup>, Kati Choi, MD<sup>4</sup>, Hebert L. DuPont, MD<sup>5,6</sup>, Zhi-Dong Jiang, DrPh<sup>5</sup>, Hamzah Abu-Sbeih, MD<sup>1</sup>, Christopher A. Sanchez<sup>2</sup>, Chia-Chi Chang, PhD<sup>2</sup>, Edwin R. Parra, MD, PhD<sup>7</sup>, Alejandro Francisco-Cruz, PhD<sup>7</sup>, Gottumukkala S. Raju, MD<sup>1</sup>, John R. Stroehlein, MD<sup>1</sup>, Matthew T. Campbell, MD<sup>8</sup>, Jianjun Gao, MD, PhD<sup>8</sup>, Sumit K. Subudhi, MD, PhD<sup>8</sup>, Dipen M. Maru, MD<sup>9</sup>, Jorge M. Blando, DVM<sup>10</sup>, Alexander Lazar, MD<sup>7,9</sup>, James P. Allison, PhD<sup>10</sup>, Padmanee Sharma, MD, PhD<sup>8,10</sup>, Michael T. Tetzlaff, MD, PhD<sup>7,9</sup>, Jennifer A. Wargo, MD, MMSc<sup>2,3,\*</sup>, and Robert R. Jenq, MD<sup>2,11,\*</sup>

<sup>1</sup>Department of Gastroenterology, Hepatology & Nutrition, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>2</sup>Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>3</sup>Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>4</sup>Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA

<sup>5</sup>Center for Infectious Disease, School of Public Health, University of Texas, Houston, TX, USA

<sup>6</sup>Kelsey Research Foundation, Houston, TX, USA

#Corresponding author: Yinghong Wang MD, PhD.

Author Contributions:

Y.W. recruited and treated patients. Y.W., D.H.W., B.A.H., V.G., K.C., H.L.D., Z.-D.J., H.A.-S. C.A.S., C.-C.C., E.R.P., A.F.-C., G.S.R., J.R.S., M.T.C., J.G., S.K.S., D.M.M., J.M.B., J.P.A., P.S., M.T.T., J.A.W., and R.R.J. completed stool and tissue immunohistochemistry studies and analyzed/interpreted data. Y.W., B.A.H., V.G., M.T.T., J.A.W., and R.R.J. prepared the manuscript.

All authors approved the manuscript.

\*Co-senior authors: Jennifer Wargo MD, MMSc; Robert Jenq MD

‡Co-first authors: Yinghong Wang MD, PhD; Diana H. Wiesenki; Beth A. Helmink MD, PhD

Competing Interests Declaration:

J.A.W and V.G. are inventors on a US patent application (PCT/US17/53,717) submitted by The University of Texas MD Anderson Cancer Center that covers methods to enhance checkpoint blockade therapy by the microbiome. J.A.W. is a clinical and scientific advisor at Microbiome DX and a consultant at Biothera Pharma, Merck Sharp, and Dohme. J.A.W. has honoraria from speakers' bureau of Dava Oncology, Bristol-Myers Squibb, Gilead, Illumina, Omniprex, Imedex and is an advisory board member for GlaxoSmithKline, Novartis, and Roche/Genentech, Astra-Zeneca. V.G. is a consultant at Microbiome DX, and reports honoraria from ExpertConnect. R.R.J. is on the scientific advisory board for Seres Therapeutics, Inc., has consulted for Ziopharm Oncology and Microbiome Dx, and holds patents licensed to Seres Therapeutics, Inc. M.T.T. serves on the advisory board for Novartis, Seattle Genetics and Myriad Genetics. J.A.W., P.S., and J.P.A. are members of the Parker Institute for Cancer Immunotherapy at MD Anderson Cancer Center. P.S. is a consultant for Bristol-Myers Squibb, Jounce Therapeutics, Helsinn, and GlaxoSmithKline and is also a stockholder from Jounce Therapeutics. J.P.A. is a consultant and stockholder for Jounce Therapeutics, receives royalties from Bristol-Myers Squibb, and has intellectual property with Bristol-Myers Squibb and Merck. The other authors declare no competing interests.

Data Availability Statement:

Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement. Sequence data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001003217.

<sup>7</sup>Department of Translational Molecular Pathology, Division of Pathology/ Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>8</sup>Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>9</sup>Department of Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>10</sup>Department of Immunology, Division of Basic Science Research, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>11</sup>Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA

## Abstract

We report the first case series of ICI-associated colitis successfully treated with fecal microbiota transplantation (FMT), with reconstitution of the gut microbiome and a relative increase in the proportion of regulatory T cells (Tregs) within the colonic mucosa. These preliminary data provide evidence that modulation of the gut microbiome may abrogate ICI-associated colitis.

---

Immunotherapy has transformed the field of oncology improving long-term survival in patients across numerous cancer types. Treatments with immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are associated with increased T cell activation and effective anti-tumor immune responses in a subset of patients, but treatment can be associated with serious immune-related adverse effects (irAEs) in some patients<sup>1</sup>. One of the most common toxicities is ICI-associated colitis. This can be quite severe and closely resembles colitis associated with autoimmune pathophysiology including inflammatory bowel disease (IBD)<sup>2,3</sup>. ICI-associated colitis is routinely treated with immunosuppressive therapy, including corticosteroids and/or agents targeting tumor necrosis factor alpha (TNF-alpha), all of which have significant side effects. Recommendations regarding optimal management of ICI-induced colitis continue to evolve<sup>4-9</sup>. Interestingly, recent randomized clinical studies suggest that other types of colitis, including *Clostridium difficile*-associated colitis and IBD, can be successfully treated by modulation of the gut microbiome with fecal microbiota transplantation (FMT)<sup>10</sup>.

Previously, we demonstrated that differential bacterial signatures comprise the gut microbiome of responders versus non-responders to ICI therapy and additionally showed that modulation of the gut microbiome of germ-free mice via FMT from patients could alter anti-tumor immunity and response to ICI therapy in gnotobiotic mice<sup>11-13</sup>. Other groups have also demonstrated differential bacterial signatures in the gut microbiome of patients who develop ICI-associated colitis<sup>14-16</sup> and have shown that targeting specific bacterial taxa may abrogate ICI-related toxicity in pre-clinical models<sup>17</sup>. However, approaches incorporating modulation of the microbiome to treat ICI-associated colitis have not yet been explored in patients. Herein, we document results from the first reported case series of two patients with refractory ICI-associated colitis successfully treated with FMT and describe

changes in the immune microenvironment following FMT, a potential mechanism of action through which modulation of the gut microbiome may impact ICI-associated colitis.

We sought to determine the impact of treatment with FMT from healthy donors in patients with refractory ICI-associated colitis and enrolled two patients onto this treatment protocol between June 2017 and January 2018 (CIND17-0036, CIND17-0058). Clinical courses for both patients are further detailed in Supplemental Figs. 1–3. The first patient was a 50-year-old female with high-grade metastatic urothelial carcinoma refractory to standard chemotherapy who was enrolled onto a trial of combined CTLA-4 and PD-1 blockade (NCT1928394). Two weeks after treatment initiation, she was hospitalized with CTCAE Grade 2 diarrhea/colitis. An infectious workup including PCR-based multiplex assay for common GI pathogens was negative, and colonoscopy demonstrated severe colitis that endoscopically resembled ulcerative colitis (Fig. 1a and Supplemental Figs. 3a and 4a). She received systemic corticosteroids, followed later by two doses of an anti-TNF-alpha agent (infliximab) as well as one dose of anti-integrin therapy (vedolizumab), but her symptoms persisted. She then received a single dose of FMT (50 grams of donor stool) via colonoscopy. The second patient enrolled was a 78-year-old male with prostate cancer refractory to chemotherapy and hormonal therapy who received two doses of ipilimumab in the context of a clinical trial (NCT02113657). Three months after treatment initiation, he was hospitalized with fever and CTCAE Grade 2 diarrhea/colitis. Infectious etiologies were excluded and colonoscopy confirmed the diagnosis of ICI-associated colitis, though with a Crohn's colitis-like presentation (Fig. 1d and Supplemental Figs. 3b and 4b). His symptoms persisted despite systemic corticosteroids, infliximab and vedolizumab. He received two doses of FMT. The source of all three FMT products was from a single healthy unrelated donor, collected at three different time points.

Both patients had complete resolution of clinical symptoms following treatment with FMT, with eventual return to normal solid daily bowel movements without further bleeding (Supplemental Fig. 3). In the first patient, complete resolution occurred gradually within 2 weeks and she was weaned off steroids in 7 days (Supplemental Fig. 3a), while the second patient experienced partial improvement of GI symptoms but with persistent ulcers on follow-up colonoscopy and recurrent abdominal pain; he experienced complete resolution after a second FMT treatment (Supplemental Fig. 3b).

Endoscopic evaluation demonstrated significant mucosal inflammation and ulceration in both patients near the time of diagnosis of ICI-colitis, without substantial improvement after systemic corticosteroids, anti-TNF and anti-integrin agents. Following FMT, marked improvement was evident on endoscopic evaluation, with reduced inflammation and resolution of ulcerations (Fig. 1a and 1d and Supplemental Figs. 3 and 4). In the first patient, analysis of immune infiltrates in the colonic mucosa demonstrated a dense inflammatory infiltrate prior to FMT with a high density of CD8+ cytotoxic T lymphocytes and a low density of CD4+ FoxP3+ T cells (Fig. 1b-c and Supplemental Figs. 5a and 6a), consistent with findings from reports of autoimmune colitis<sup>18,19</sup>. Following FMT, there was a substantial reduction in CD8+ T-cell density with a concomitant increase in CD4+ FoxP3+ (Fig. 1b-c and Supplemental Figs. 5a and 6a), offering a potential mechanism through which FMT could abrogate ICI-associated toxicity. In the second patient, the density of all T cell

subtypes analyzed decreased following FMT, but the CD4+ T cell population was relatively spared compared to the CD8+ T cell population, with persistence again noted for CD4+ and FoxP3+ cells (Figs. 1e-f and Supplemental Figs. 5b, 6b and 7).

Importantly, stool samples were collected from patients prior to FMT and serially following FMT to assess the diversity and composition of the microbiome before and after intervention via 16S sequencing (Supplemental Figs. 1–2). Results demonstrated variable pre-treatment alpha diversity compared to the healthy FMT donor (Fig. 2a). There was no observable trend in alpha diversity following treatment, measured by the inverse Simpson's index. Numbers of observed OTUs, however, did consistently rise following each FMT in both patients, though in both cases they would later come back down (Fig. 2a). Principal coordinates analyses of unweighted UniFrac distances demonstrated that the gut microbiome of patients became most similar to the FMT donor immediately following treatment, but, in both cases later deviated away though remaining distinct compared to pre-FMT (Fig. 2b). An evaluation of unique 16S sequences<sup>20</sup> detectable in patient pre-FMT baseline samples and FMT products was used to determine probable bacterial origins in longitudinal samples, demonstrating considerable abundances of bacteria of donor origin that stably joined the patient's intestinal microbiome with each FMT procedure (Fig. 2c).

We next assessed bacterial taxa present at time of colitis in these patients as well as compositional changes in the gut microbiome following treatment with FMT. Bacterial taxa present at time of colitis were quite disparate between the two patients, with a predominance of *Clostridia* and a notable absence of bacteria shown to be protective against ICI-associated colitis and IBD such as *Bacteroidia*<sup>14,16</sup> and Verrucomicrobiae<sup>21</sup> respectively in the first patient and a predominance of *Gammaproteobacteria* (predominantly *Escherichia*) in the second patient, which is commonly seen in perturbed intestinal states<sup>22</sup>. Immediately following FMT in the first patient, donor FMT-derived bacteria had effectively colonized the intestinal tract, with nearly 75% of the sequences uniquely attributable to the FMT donor microbiome and a notably higher abundance of *Akkermansia* (Fig. 2d-e). By week 7 after FMT, *Akkermansia* now only accounted for a small portion of her microbiome and there was further expansion of *Clostridia* which were largely patient-derived in origin (Fig. 2d, left and 2e, left). Of note, the patient also showed an expansion of *Bifidobacterium* after FMT, which recently was reported to abrogate ICI-related toxicity in a murine model<sup>17</sup> (Fig. 2d, left and 2e, left). In the second patient, there was a notable increase in the abundance of *Blautia* and *Bifidobacterium* species after FMT, which have been associated with reduced intestinal inflammation (Fig. 2d, right and 2e, right)<sup>23,17</sup>. In addition to this, he had a decrease in the abundance of potentially pathogenic *Escherichia* and an increase in potentially beneficial *Bacteroides* after his first FMT (Fig. 2d, right and 2e, right). After his second FMT, he had a higher abundance of *Escherichia* and eventual decrease in *Bacteroides*; however, his gastrointestinal symptoms steadily continued to improve (Fig. 2d, right and 2e, right).

Together, these cases provide provocative and novel evidence that modulation of the gut microbiome via FMT can be associated with significant and rapid improvement of refractory ICI-associated colitis with early insights into potential mechanisms; however, significant limitations exist with this very small cohort and additional studies are needed to assess the utility of this approach as well as to provide further mechanistic insight. Given the

widespread application of ICI with expanding indications across cancer types, it is anticipated that there will be an increased incidence in ICI-associated colitis and other irAEs. Thus, further investigations building on this approach are critically needed.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements of Funding Support:

Andrew Sabin Family Fellows Program (private donation): J.A.W.

MD Anderson Cancer Center's Melanoma Moon Shot Program (710499-80-111538-19): J.A.W.

American Association for Cancer Research Stand Up to Cancer (SU2C-AACR-IRG-19-17): J.A.W.

National Institutes of Health (R01 CA219896-01A1): J.A.W.

National Institutes of Health (R01 HL124112): R.R.J.


Cancer Prevention and Research Institute of Texas Grant (RR160089): R.R.J.

## References

1. Michot JM, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer* 54, 139–148 (2016). [PubMed: 26765102]
2. Cramer P & Bresalier RS Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. *Curr Gastroenterol Rep* 19, 3 (2017). [PubMed: 28124291]
3. Chen JH, Pezhohu MK, Lauwers GY & Masia R Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. *Am J Surg Pathol* 41, 643–654 (2017). [PubMed: 28296676]
4. Dadu R, Zobniw C & Diab A Managing Adverse Events With Immune Checkpoint Agents. *Cancer J* 22, 121–129 (2016). [PubMed: 27111908]
5. Bertrand A, Kostine M, Barnetche T, Truchetet ME & Schaeffer T Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC Med* 13, 211 (2015). [PubMed: 26337719]
6. Horvat TZ, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. *J Clin Oncol* 33, 3193–3198 (2015). [PubMed: 26282644]
7. Beck KE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. *J Clin Oncol* 24, 2283–2289 (2006). [PubMed: 16710025]
8. Johnston RL, Lutzky J, Chodhry A & Barkin JS Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. *Dig Dis Sci* 54, 2538–2540 (2009). [PubMed: 19104936]
9. Minor DR, Chin K & Kashani-Sabet M Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. *Cancer Biother Radiopharm* 24, 321–325 (2009). [PubMed: 19538054]
10. Borody TJ & Khoruts A Fecal microbiota transplantation and emerging applications. *Nat Rev Gastroenterol Hepatol* 9, 88–96 (2011). [PubMed: 22183182]
11. Gopalakrishnan V, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science* 359, 97–103 (2018). [PubMed: 29097493]
12. Matson V, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science* 359, 104–108 (2018). [PubMed: 29302014]

13. Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science* 359, 91–97 (2018). [PubMed: 29097494]
14. Dubin K, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. *Nat Commun* 7, 10391 (2016). [PubMed: 26837003]
15. Vetizou M, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science* 350, 1079–1084 (2015). [PubMed: 26541610]
16. Chaput N, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. *Ann Oncol* 28, 1368–1379 (2017). [PubMed: 28368458]
17. Wang F, Yin Q, Chen L & Davis MM Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade. *Proc Natl Acad Sci U S A* 115, 157–161 (2018). [PubMed: 29255057]
18. Kappeler A & Mueller C The role of activated cytotoxic T cells in inflammatory bowel disease. *Histol Histopathol* 15, 167–172 (2000). [PubMed: 10668207]
19. Nancey S, et al. CD8+ cytotoxic T cells induce relapsing colitis in normal mice. *Gastroenterology* 131, 485–496 (2006). [PubMed: 16890603]
20. Edgar RC UNOISE2: Improved error-correction for Illumina 16S and ITS amplicon reads. (2016).
21. Png CW, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. *Am J Gastroenterol* 105, 2420–2428 (2010). [PubMed: 20648002]
22. Litvak Y, Byndloss MX, Tsolis RM & Baumler AJ Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. *Curr Opin Microbiol* 39, 1–6 (2017). [PubMed: 28783509]
23. Jenq RR, et al. Intestinal *Blautia* Is Associated with Reduced Death from Graft-versus-Host Disease. *Biol Blood Marrow Transplant* 21, 1373–1383 (2015). [PubMed: 25977230]






**Figure 1:** Endoscopic changes and characterization of colonic mucosal infiltrate throughout clinical course for Patient 1 (a-c) and Patient 2 (d-f). **(a)** Changes in colonic mucosa as assessed by full colonoscopy. Near the time of diagnosis (row 1), multiple large ulcers and diffuse inflammatory exudate are present (in the distal 40cm of the colon only, with the normal appearing proximal colon) and remain despite months of treatment with steroids and biologic immunosuppressive agents (steroid + 2 doses infliximab + 1 dose vedolizumab) (row 2). Approximately one month after FMT (row 3), colonic mucosa exhibits grossly normal vasculature, minimal patchy erythema, and near-complete healing of prior ulcers. Yellow arrows point to ulcerative lesions. This patient had full colonoscopic evaluations that examined every segment of the colon (ascending, transverse, descending, sigmoid and rectum). Endoscopy was performed once at each time point. Given the qualitative nature of endoscopic data collection and inability to provide true statistical analyses, we chose to include multiple other representative photos from the same colonoscopic evaluations. Additional representative photos are presented in Supplemental Figure 4a. **(b)** Immunohistochemical analysis of mucosal biopsies of the colon/rectum prior to, and following, FMT. A single slide representative of the endoscopic biopsy specimen as a whole was stained for each patient for each time point. Representative slides from additional time points are included in Supplemental Figure 5a. **(c)** Analysis of changes in the density immune cell subsets (CD8 red squares, CD4 blue circles, FOXP3 black triangles) over time,

expressed as a fold change from baseline based on total densities of cells expressing these markers (absolute densities are presented in Supplemental Figure 6a). Timepoints include time of diagnosis, prior to FMT, following steroids and biologic immunosuppression and following FMT. Date of FMT is represented by dotted vertical line and is designated Day 0. These data represent the average cell density from 4 regions of interest (ROIs) per sample (single slide per patient at each time point) with each ROI measuring 500  $\mu\text{m}$  x 500  $\mu\text{m}$  for a total of 0.25  $\text{mm}^2$ . We report the mean # IHC-positive cells/ $\text{mm}^2$  divided by the mean # IHC-positive cells/ $\text{mm}^2$  at baseline. **(d)** Changes in colonic mucosa as assessed by full colonoscopy. Near the time of diagnosis (row 1), multiple large ulcers and inflammatory exudate is present (throughout the entire colon) and remains after unsuccessful treatment with steroids and biologic immunosuppressive agents (steroid + 2 doses infliximab + 4 doses vedolizumab) (row 2). There is notable improvement following first FMT (row 3) but residual ulcers remain. Following second FMT (row 4) we note near complete resolution of all ulcerative lesions. Again full endoscopic examinations were performed, once for each time point. Additional representative photos from the colonoscopic evaluation are shown in Supplemental Figure 4b. **(e)** Immunohistochemical analysis of mucosal biopsies of the colon/rectum taken prior to first FMT and following first FMT. A single slide representative of the endoscopic biopsy specimen was stained for each patient for each time point. Representative slides from additional time points are included in Supplemental Figure 5b. **(f)** Analysis of changes in the density immune cell subsets (CD8 red squares, CD4 blue circles, FOXP3 black triangles) over time, expressed as a fold change from baseline based on total densities of cells expressing these markers (absolute densities are presented in Supplemental Figure 6b). These data represent the average cell density from 4 regions of interest (ROIs) per sample (single slide per patient at each time point) with each ROI measuring 500  $\mu\text{m}$  x 500  $\mu\text{m}$  for a total of approximately 1  $\text{mm}^2$ . We report the mean # IHC-positive cells/ $\text{mm}^2$  divided by the mean # IHC-positive cells/ $\text{mm}^2$  at baseline. Date of first (Day 0) and second FMT (Day 67) are represented by dotted vertical lines.





**Figure 2:** *Microbiome analysis of patient and donor intestinal bacteria by 16S deep sequencing.* The patients' stool microbiomes were longitudinally sampled at indicated time points before and after FMT, along with samples from the FMT donor. Between 3380 and 42,776 sequences were obtained for each sample (average 10,003). **(a)** Alpha diversity, quantified by the inverse Simpson index after rarefying to 3000 sequences, as well as total observed OTU numbers, was evaluated for patient and FMT donor samples. **(b)** Using principal coordinate analysis of unweighted UniFrac distances, microbiome samples from **(a)** are depicted in

space with more similar samples located closer together. **(c)** Bacterial 16S sequences from samples in **(a)** were classified by origin (unique to patient baseline, unique to donor, present in both patient baseline and donor, or absent in both patient baseline and donor). **(d)** Sequences were classified by taxonomy at the Class level. **(e)** Changes in the abundances of top varying 10 bacterial genera over time.